By Stanton R. Mehr

The Clinical Trials reported in this issue include: PHASE III: 1) What Factors Predict Prognosis in Patients With Malignant Pleural Mesothelioma? 2) Treatment for Patients With High-Risk Postoperative Breast Cancer PHASE II: 1) Epratuzumab Plus Rituximab Equals Non-Hodgkin's Lymphoma Response 2) Topotecan Added to Twice-Daily Chemoradiation to Treat Limited- Stage, Small-Cell Lung Cancer 3) First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer 4) Radiotherapy for Nasal Squamous Cell Carcinoma Therapy PHASE I/II: 1) A New Combination Approach for Advanced-Stage Germ-Cell Tumors

Articles in this issue include: 1) South Korea: Is Intermittent Imatinib Therapy for Chronic Myelogenous Leukemia an Option? Genetic Marker Predicts Treatment Resistance and Poor Outcomes in Esophageal Cancer 2) France: Pelvic Radiation in Addition to Prostate Radiotherapy for Localized Prostate Cancer 3) Multiple Sites in Europe: European Guidelines for Oral Mucositis Released 4) Japan: The Care of Delirium in Terminal Illness and Bereavement Needs 5) The Netherlands: Cancer Pain and Adherence to Analgesic Treatment 6) Switzerland, Belgium & France: Confirmation of Gene Expression Link to Chemotherapy Response in Breast Cancer

Clinical Trial Reports in this issue include: Phase IV: 1) Long-Term Aspirin Therapy Reduces Colorectal Cancer Risk Phase III: 1) Does Adding Cisplatin to Adjuvant Chemotherapy Improve Outcomes in Advanced Gastric Cancer? 2) FOLFIRI Plus Bevacizumab Provides Better Survival Than Other Irinotecan-Containing Regimen in First-Line Colorectal Cancer Phase II: 1) Single-Agent Activity of Sunitinib in Refractory Non������¢���¯���¿���½���¯���¿���½Small Cell Lung Cancer 2) The Importance of Targeting Androgen Receptor Signaling for Prostate Cancer Response Rate 3) Improving Survival in Gastrointestinal Stromal Tumor 4) Improving Overall Survival in Patients With Hormone- Resistant Prostate Cancer 5) Breast Cancer Stem Cells Decreased With Neoadjuvant Lapatinib Phase I/II: 1) Patients With Recurrent Glioblastoma May Benefit From Implant Combinations

Phase IV: 1) Cancer Risks and Postmenopausal Hormone Link Confirmed Phase III: 1) Do Vitamins Protect Against Lung Cancer? 2) Longer Life Expectancy in Pancreatic Cancer When Gemcitabine Is Added to Chemotherapy 3) Outcomes Improve With Letrozole Treatment in Women With Early-Stage Breast Cancer 4. Pemetrexed vs. Docetaxel for Non-Small Cell Lung Cancer Treatment Phase II: 1) Talactoferrin-Alfa Treatment for Non-Small Cell Lung Cancer 2) Advanced Carcinoid Systemic Therapy

German researchers sought to confirm the results of a previous Japanese trial that found patients with extensive-disease small–cell lung cancer (ED SCLC) treated with irinotecan plus cisplatin lived longer than subjects given therapy with etoposide plus cisplatin.